このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer (MISO)

2026年11月6日 更新者:Qinglei Gao、Tongji Hospital

A Phase 2 Study of Mirvetuximab Soravtansine (MIRV) in Combination With Suvemcitug for the Treatment of Folate Receptor Alpha (FRα)-Expressing Partially Platinum-Sensitive Ovarian Cancer (MISO)

This is a prospective, single-arm, phase II study designed to evaluate the efficacy and safety of mirvetuximab soravtansine combined with suvemcitug in patients with FRα-positive partially platinum-sensitive recurrent ovarian cancer.

Approximately 80 patients will be enrolled. Eligible patients must have recurrent high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with FRα expression and disease recurrence occurring 6 to 12 months after completion of platinum-based chemotherapy.

Participants will receive mirvetuximab soravtansine and suvemcitug every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. Tumor response will be assessed according to RECIST version 1.1.

The primary objective is to evaluate the objective response rate (ORR). Secondary objectives include duration of response (DOR), progression-free survival (PFS), overall survival (OS), CA125 response, and safety outcomes. Exploratory analyses will assess the relationship between FRα expression, other biomarkers, and clinical outcomes.

調査の概要

研究の種類

介入

入学 (推定)

80

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Hubei
      • Wuhan、Hubei、中国、430030
        • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Signed written informed consent and able to comply with the protocol-specified visits and related procedures.

  2. Female patients aged ≥18 years.

  3. Patients with histologically or cytologically confirmed high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

  4. Recurrence after prior standard platinum-based chemotherapy with or without bevacizumab ± PARP inhibitor, with the date of diagnosis of recurrence being 6-12 months from the last platinum-based chemotherapy.

  5. Patients with a BRCA mutation must have received PARP inhibitor therapy.

  6. Patients must have experienced disease progression during or after the most recent anticancer therapy received.

  7. Tumor FRα expression has been determined by the VENTANA FOLR1 assay to be ≥25% (requiring ≥25% of tumor cells with staining intensity ≥2+ after FRα staining).

  8. Patients must provide archived tumor tissue block or sections for central laboratory FRα testing and exploratory biomarker analysis. Tissue wax blocks are preferred; if wax blocks cannot be provided, no fewer than 10 unstained sections should be provided.

  9. Patients must have at least one evaluable lesion per RECIST v1.1 (determined by the investigator via imaging).

  10. Eastern Cooperative Oncology Group performance status (ECOG PS) must be 0-2.

  11. Patients must have received at least 1 but no more than 2 lines of prior systemic anticancer chemotherapy:

    1. Neoadjuvant therapy ± adjuvant therapy is considered as 1 line of therapy;
    2. A change in treatment due to toxicity in the absence of disease progression is considered part of the same line of therapy (i.e., not counted separately).
  12. Adequate major organ function, and the patient is considered by the investigator to be suitable for treatment with mirvetuximab soravtansine combined with suvemcitug, defined as:

    1. Absolute neutrophil count (ANC) ≥1.5 × 10^9/L (1,500/μL), and no use of G-CSF within the prior 10 days, or no use of long-acting WBC growth factors within the prior 20 days;
    2. Platelet count ≥100 × 10^9/L (100,000/μL) with no platelet transfusion within the prior 10 days;
    3. Hemoglobin ≥9.0 g/dL with no packed red blood cell (PRBC) transfusion within the prior 21 days;
    4. Serum creatinine ≤1.5 × upper limit of normal (ULN);
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × ULN;
    6. Serum bilirubin ≤1.5 × ULN (patients with Gilbert's syndrome may be enrolled if total bilirubin <3.0 × ULN);
    7. Serum albumin ≥2 g/dL.
  13. All toxicities related to prior treatment (except alopecia) must have recovered to ≤ Grade 1 per CTCAE v5.0.

  14. Any major surgery the patient has undergone must have been completed at least 4 weeks prior to the first dose of mirvetuximab soravtansine and suvemcitug, and postoperative complications from prior surgical treatment must have resolved or be stable.

  15. The subject's life expectancy is assessed by the investigator to be at least 12 weeks.

Exclusion Criteria:

  1. Concurrent participation in another clinical study.
  2. Patients with endometrioid, clear cell, mucinous, or sarcoma histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian tumors.
  3. Patients whom the investigator considers to have other serious systemic diseases (including active infection, non-infectious interstitial lung disease, clinically significant cardiovascular or cerebrovascular disease within 6 months prior to the first dose, etc.) or other reasons that make them unsuitable for participation in this clinical study.
  4. Known prior hypersensitivity to monoclonal antibody therapy or maytansinoids, or to the study drug and/or any of its excipients.
  5. Patients with active or chronic corneal disease, history of corneal transplant, or active eye disease requiring continuous treatment/monitoring, for example: uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injection therapy, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision.
  6. Patients with pleural effusion, pericardial effusion, or ascites that cannot be controlled by drainage or other methods should be excluded, except for small amounts of fluid that are asymptomatic or do not require clinical intervention.
  7. Patients who have previously received mirvetuximab soravtansine or other FRα-targeted therapies.
  8. Known active central nervous system (CNS) metastases and/or leptomeningeal disease. Subjects with untreated but asymptomatic brain metastases, or those with imaging evidence of sustained progression-free status for at least 4 weeks after treatment and no need for hormones or anti-epileptic therapy for at least 2 weeks, may be considered for enrollment.
  9. Pregnant or breastfeeding women. Women of childbearing potential must agree to take highly effective contraceptive measures during the study drug period and for at least 7 months after the last dose of study drug. Women of childbearing potential are defined as fertile women from menarche until menopause, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.
  10. Patients who have received anti-tumor therapy or participated in a clinical study and received an investigational drug within 2 weeks prior to the first dose of this study.
  11. Patients with hypertension that cannot be reduced to the normal range with antihypertensive medication (systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg).
  12. Patients with NYHA Class III-IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) < 50% as indicated by echocardiography
  13. Patients with proteinuria (urine protein > 1+ found during screening; or urine protein 1+ that does not return to normal upon repeat testing within 24 hours);
  14. Patients with a clear tendency for gastrointestinal bleeding, including the following conditions: presence of a local active ulcer lesion with fecal occult blood (++) making them ineligible for enrollment; history of melena or hematemesis within 2 months; presence of high bleeding risk: Grade ≥ 3 bleeding events within the past 6 months, hemoptysis ≥ 2.5 mL per episode; imaging suggesting tumor erosion into major blood vessels; or investigator judgment that the bleeding risk is unacceptable;
  15. Presence of high risk of gastrointestinal perforation/fistula: gastrointestinal perforation or active peptic ulcer within the past 6 months; or pelvic tumor significantly invading the bladder/rectum with potential risk of fistula (investigator judgment);
  16. Coagulation abnormalities (INR > 1.5, APTT > 1.5 × ULN) with a bleeding tendency;
  17. Long-term unhealed wounds or fractures; major surgery or severe traumatic injury, fracture, or ulcer within 4 weeks.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Mirvetuximab Soravtansine + Suvemcitug

Patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer will receive mirvetuximab soravtansine combined with suvemcitug. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or other protocol-specified discontinuation criteria.

Mirvetuximab soravtansine is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody linked to the maytansinoid DM4. It is administered intravenously in combination with suvemcitug for the treatment of patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.

Suvemcitug is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). In this study, suvemcitug is administered intravenously in combination with mirvetuximab soravtansine to evaluate the efficacy and safety in patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall Response Rate(ORR)
時間枠:up to 24 months

Investigator-assessed ORR, including confirmed best overall response of CR or PR per RECIST v1.1.

up to 24 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Progression-Free Survival(PFS)
時間枠:up to 24 months

Investigator-assessed PFS: Defined as the time from first dose to the first documented PD per tumor assessment follow-up or death from any cause (whichever occurs first).

up to 24 months
During of response*(DoR)
時間枠:up to 24 months

Investigator-assessed DOR: For patients who achieve an objective response, DOR is defined as the time from first meeting CR/PR criteria (whichever occurs first) to the date of PD or death from any cause (whichever occurs first).

up to 24 months
Overall Survival (OS)
時間枠:up to 24 months

OS: Defined as the time from first dose to death from any cause (for patients lost to follow-up prior to death, the last follow-up date is typically used as the date of death).

up to 24 months
CA125 response
時間枠:up to 24 months

CA125 response: Assessed according to GCIG (Gynecologic Cancer InterGroup) criteria.

In the GCIG CA125 criteria, CA125 response is defined as a reduction in CA125 level of at least 50% after treatment, maintained for at least 28 days. CA125 assessment can only be performed if the patient's CA125 level is greater than twice the upper limit of normal within the 2 weeks before the start of treatment.

up to 24 months
Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). (Assessed by the investigator per CTCAE criteria.)
時間枠:up to 24 months
up to 24 months
Incidence of Grade ≥3 treatment-related adverse events (TRAEs) assessed by the investigator. (Assessed by the investigator per CTCAE criteria.)
時間枠:up to 24 months
up to 24 months

その他の成果指標

結果測定
時間枠
Correlation between baseline tumor tissue FRα expression levels and other exploratory biomarker characteristics with ORR, PFS, DOR, and treatment-related adverse events.
時間枠:up to 24 months
up to 24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月10日

一次修了 (推定)

2028年6月30日

研究の完了 (推定)

2028年6月30日

試験登録日

最初に提出

2026年11月6日

QC基準を満たした最初の提出物

2026年11月6日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する